Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer

ABSTRACT:

Background

MammaPrint (MMP) helps clinicians identify the ideal time for adjuvant treatment for patients with early HR+/HER2− breast cancer. We aimed to validate a nomogram designed to predict probability of low risk of MMP results and to evaluate the difference in survival outcome between two groups divided by nomogram score.

Methods

In this retrospective cohort study, we evaluated 172 patients from Asan Medical Center, Seoul, Korea, who underwent breast cancer surgery and MMP during 2020–2021. First, we validated the nomogram by calculating the area under the curve (AUC) and using calibration. Additionally, with the data of 1,835 T1-3N0-1M0 HR+/HER2− patients from Asan Medical Center during 2010–2013, we compared the disease-free survival (DFS), overall survival (OS), a

SUBMITTER: Hwang Y 

PROVIDER: S-EPMC9789221 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature